The clinicopathological significance of HES1 promoter hypomethylation in patients with colorectal cancer
OncoTargets and Therapy Dec 14, 2017
Wu Y, et al. - Researchers here determine the methylation status of the Hairy/enhancer of split 1 (HES1) promoter and correlations with clinicopathological parameters and prognosis in colorectal cancer (CRC). Based on the findings, they conclude that promoter hypomethylation upregulates HES1 expression and plays an important role in the progression and prognosis of CRC patients.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
